|
1）Rossi A, Torri V, Garassino MC, et al. The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer treatment reviews. 2013. [Epub ahead of print]
|
|
|
|
|
2）Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007; 97: 453-7
|
|
|
|
|
3）Terashima M, Kitada K, Ochiai A, et al; Group A-G. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clinical cancer research. 2012; 18: 5992-6000
|
|
|
|
|
|
4）Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009; 27: 5838-47
|
|
|
|
|
|
5）Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97
|
|
|
|
|
|
6）Nishikawa K, Nashimoto A, Miki A, et al. Result of HER2 status in Japanese metastatic gastric cancer: Prospective cohort study (JFMC44-1101). J Clin Oncol. 2012; 30: (suppl 34: abstr 10)
|
|
|
|
|
|
7）Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011; 104: 1372-6
|
|
|
|
|
|
8）Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-21
|
|
|
|
|
|
9）Sugimoto N, Tsuda M, Okamoto W, et al. A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1). J Clin Oncol. 2013; 31 (suppl: abstr 4072)
|
|
|
|
|
|
10）Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011; 105: 1273-8
|
|
|
|
|
|
11）Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell biochem and Biophys. 2012; 62: 221-8
|
|
|
|
|
|
12）Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-92
|
|
|
|
|
|
13）Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005; 41: 1649-54
|
|
|
|
|
|
14）Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori. 2005; 91: 513-21
|
|
|
|
|
|
15）Fessler SP, Wotkowicz MT, Mahanta SK, et al. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast cancer Res Treat. 2009; 118: 113-24
|
|
|
|
|
|
16）Zagouri F, Sergentanis TN, Chrysikos D, et al. Pertuzumab in breast cancer: a systematic review. Clinical Breast Cancer. 2013; 13: 315-24
|
|
|
|
|
|
17）Lewis Phillips GD, Fields CT, Li G, et al. Dual targeting of HER2-positive cancer with trastuzumab-emtansine (T-DM1) and pertuzumab: critical role for neuregulin blockade in anti-tumor response to combination therapy. Clinical Cancer Research. 2013. [Epub ahead of print]
|
|
|
|
|
|
18）Pazo Cid RA, Anton A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol. 2013; 85: 350-62
|
|
|
|
|
|
19）Asaoka Y, Ikenoue T, Koike K. New targeted therapies for gastric cancer. Expert Opin Investig Drugs. 2011; 20: 595-604
|
|
|
|
|